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1. Introduction 
The biological effects of insulin and NSILA, a poly- 
peptide purified from human serum, on adipose tissue 
and isolated fat cells have been shown to be identical 
[l-5 ] . Among these, carrier-mediated stimulation of 
glucose uptake across the fat cell membrane [2] and 
inhibition of epinephrine-induced cyclic AMP-release 
from adipose tissue [6] suggest hat the mechanism by 
which both hormones act at the cell membrane level 
is also the same. Therefore, we expected that the 
primary step of action of insulin and NSILA on 
adipose tissue involves binding to the same membrane 
acceptor site. To test this hypothesis binding studies 
with 1251-labelled insulin and NSILA were performed 
with isolated rat fat cells. The results are compatible 
with the presence of two membrane binding sites for 
NSILA on adipocytes, one which appears to be 
identical with the insulin acceptor, but with a lower 
affinity for NSILA, and a second one which displays 
specificity and high affinity for NSILA, but not for 
insulin. 
2. Materials and methods 
2.1. Animals 
Male, normal fed Zbz-Cara (formerly Osborne- 
Mendel) rats, weighing between 100 and 120 g were 
used for ail experiments. Fat cells were prepared from 
epididymal fat pads by the method of Rodbell [7] 
*Reprint requests should be addressed to Dr .I. Zapf. 
North-Holland Publishing Company - Amsterdam 
using crude collagenase (Worthington Biochemical 
Corp.). 
2.3. Experimental 
All NSILA preparations (specific biological activity 
ranging from 3.8 to 200 mu/ml, standardized in the 
fat pad assay using insulin as reference), reduced 
aminoethylated (RAE)-NSILA and whale insulin 
were kindly provided by Drs E Rinderknecht and 
R. E. Humbel. Glucagon was a gift from Elli Lilly, 
ACTHi _ 24 (Synacthen) from Ciba Geigy, Basel; 
human growth hormone (HGH) was donated by 
Dr M. Zachmann. 
NSILA (- 200 mu/ml, SO-60% pure; [8] ) and 
whale insulin (same amino acid sequence as porcine 
insulin) were iodinated according to the method of 
Hunter and Greenwood [9], modified as described 
earlier [lo] . 
Incubation of the cells was carried out in 20 ml 
plastic tubes in a shaking water bath for 60 min at 
24°C in Krebs-Ringer-bicarbonate buffer containing 
1% human serum albumin (HSA; from the Swiss 
Red Cross, Bern) and 20 mg/lOO ml of glucose. 1 ml 
of the incubation mixture usually contained between 
20 and 30 mg of fat cells and between 0.5 and 1 .O PU 
(200 000-400 000 cpm) of ‘251-labelled NSILA or 
between 10 and 20 PU (200 000-400 000 cpm) of 
1251-labelled insulin in addition to the unlabelled 
peptides. At the end of the incubation the cells were 
filtered on Millipore filters (EAWP) under a soft 
vacuum and rinsed three-times with 3 ml of ice-cold 
Dulbecco buffer containing 0.1% HSA. The dried 
filters were counted in 5 ml of Instagel (Packard) in a 
liquid scintillation counter (Nuclear, Chicago). All 
samples were run in triplicate. 
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3. Results and discussion 
Fig.lA shows the displacement of 1251-labelled 
insulin by increasing concentrations of unlabelled 
insulin and by three NSILA-preparations of different 
purity. Specific binding to 20 mg of fat cells of 
1251-labelled insulin (= difference between binding in 
the absence and presence of 100 mu/ml of cold 
insulin) was 1 .15 * 0.33% (mean f S.D. of 
14 experiments) of the added radioactivity. Between 
40 and 60% of the total binding accounted for non- 
specific binding (in the presence of 100 mu/ml of cold 
insulin). Half-maximal displacement was achieved by 
- 2 X lo-’ M insulin which is in good agreement with 
the data reported by Gammeltoft and Gliemann [ 1 l] 
and by Livingston et al. [ 121. As observed earlier [ 131 
NSILA displaced labelled insulin. The displacing 
potency of the three NSILA-preparations correlated 
reasonably well with their specific biological activities 
measured in the fat pad assay. 2 mu/ml caused near 
maximal displacement (> 90%) compared to the dis- 
placement observed in the presence of 100 mu/ml of 
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Fig.2. Competition between lZSI-labelled NSILA and 
unlabelled NSILA of different purity for binding to isolated 
rat fat cells. Incubation conditions are described in materials 
and methods. Each point represents the mean of 6-9 
incubations. Nonspecific binding in the presence of 1 mu/ml 
of cold NSILA has been subtracted from all values. Calcula- 
tion of molar concentrations as in fig.lA. 
cold insulin. However, the displacing potency of 
NSILA was only - l/35 (half-maximal displacement 
at - 7 X 10e8 M NSILA) of that of cold insulin. 
A potency ratio of - l/60 between NSILA and insulin 
was found when the stimulation of [ l-14C]glucose 
oxidation by the two peptides in isolated fat cells was 
compared (fig.1 B: half-maximal stimulation by insulin: 
- 6 X lo-” M; by NSILA: - 3.4 X lo-’ M). 
As shown in fig.2, 1251-labelled NSILA was bound 
Fig.1. (A) Competition between ‘251-labelIed whale insulin and 
increasing concentrations of unlabelled whale insulin or of 
unlabelled NSILA of different purity for binding to isolated 
rat fat cells. Incubations were carried out as described in 
materials and methods. Nonspecific binding in the presence of 
100 mu/ml of cold insulin or of 2 mu/ml of cold NSILA has 
been subtracted from all values and the latter have then been 
expressed as percent of maximal specific binding. Each point 
represents the mean of at least 3 different experiments 
carried out in triplicates each. Bars give the SEMs, which have 
been left out for clearness on the NSILA curve. Molar 
concentrations of NSILA have been calculated on the basis of 
a molecular weight of 5800 and a specific biological activity 
for pure NSILA of 400 mU/mg [ 151. (B) Stimulation of 
[l-‘4C]glucose oxidation by whale insulin and NSILA 
(specific biological activity: 70 mU/mg) in isolated rat fat 
cells. Experimental procedure as described in Materials and 
methods. All values are expressed as % of maximal stimulation 
obtained at 7 X 10ml’ M insulin. Each point represents the 
mean of 4 incubations; bars give the SEM. Calculation of 
molar concentrations of NSILA as in fig.lA. 
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to isolated fat cells and displaced by cold NSILA. 
Binding of ‘251-NSILA was linear between 10 and 
80 mg/ml of fat cells, equilibration of binding was 
reached after 20 min of incubation at 24°C (not 
shown). When ‘2SI-NSILA containing medium was 
used for a second binding experiment with fresh fat 
cells after a 60 min incubation in the presence of fat 
cells, no loss of binding was detectable (not shown). 
Hence, degradation of labelled NSILA by fat cells 
seems insignificant during the time chosen for the 
binding experiments (60 min). 
Nonspecific binding determined in the presence of 
1 mu/ml of cold NSILA was between 20 and 40% of 
the total radioactivity added. 100 pU/ml of cold 
NSILA caused more than 90% displacement of the 
specifically bound label. Specific binding of ‘251-NSILA 
was 0.46 It 0.08% per 20 mg of fat cells (mean + S.D. 
of 9 experiments). The displacing potency of four 
different NSILA-preparations agreed more or less with 
their specific biological activities determined in the 
fat pad assay. Half-maximal displacement was observed 
at approximately lo-’ M of cold NSILA, a figure 
which lies within the same range as the KD-value 
determined in chick embryo fibroblasts [lo]. Human 
growth hormone (HGH), ACTH and glucagon did not 
compete for binding of ‘251-NSILA, and reduced 
aminoethylated NSILA (RAE-NSILA), which is 
inactive in the fat pad assay, interfered with binding of 
12SI-NSILA only at much higher concentrations 
(table 1). In contrast, insulin did not displace “‘1. 
NSILA, but rather consistently enhanced binding of 
the tracer (table 1). This finding has also been 
observed in the perfused rat heart [ 141, but remains 
unexplained at the present time. 
The results obtained from the experiments shown 
in fig.1 and fig.2 suggest he presence of two different 
binding sites for NSILA in rat adipocytes: one which 
is likely to be identical to the insulin binding site, 
but which displays a much lower affinity to NSILA 
than to insulin, and another one which is specific for 
NSILA. Further evidence for the presence of two 
different binding sites was obtained by the experiments 
shown in fig.3: Fat cells were preincubated with or 
without an excess of cold NSILA (500 pU/ml). They 
were then washed and their remaining binding capacity 
for labelled insulin (fig.3A) and labelled NSILA (fig.3B) 
was determined. Prior to washing binding of 12’1- 
insulin in the presence of an excess of cold NSILA was 
Table 1 
Unlabelled 
peptides added 
&ml of Total binding of % of total 
hormone protein added “‘1-NSILA binding 
cpm/ml (n = 3) 
none _ 2220 * 37 100 
NSILA (3.8 mU/mg) 0.630b 500 * 69 23 
RAE-NSILA” 0.006b 2368 f 184 107 
RAE-NSILA” 0.063b 1790 * 96 81 
RAE-NSILAa 0.630b 1596 + 67 72 
human growth 
hormone 30 2053 * 46 92 
ACTH, --24 
(Synacthen) 2s 2436 f 147 109 
Glucagon 0.400 2200 f 94 100 
Insulin 0.400 3326 + 119 150 
Fat cells (25 mg/ml) were incubated for 60 min at 24°C in the presence of 
‘251-labelled NSILA (-- 0.5 pU/ml, - 300 000 cpm) together with the peptides 
given above. Binding of the tracer was measured as described in materials and 
methods. 
aRAE-NSILA: reduced aminoethylated NSILA (specific biological activity in the 
fat pad assay before reduction and aminoethylation: 17 mU/mg. 
bFor NSILA the amount of hormone protein has been expressed in terms of 
pure peptide (specific biological activity - 400 mU/mg. 
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F’ig.3. (A) Binding of ‘Z51-labelled insulin by fat cells 
preincubated with cold NSILA (specific biological activity 
3.8 mU/mg) without or with prior washing after preincuba- 
tion. Fat cells (22 mg/ml) were preincubated for 30 min at 
24°C in Krebs-Ringer bicarbonate buffer/l% HSA. 1 ml of 
the same buffer containing - 10 ~.IU of ‘ZSl-labelled insulin 
was added and incubation was continued for another 
60 min at 24°C. Controls were preincubated without or 
with 500 pU/ml of cold NSILA for 30 min; however, 
‘251-insulin was added without prior washing of the cells. 
Bars give the SEM of 4 incubations. (B) Binding of ‘251-labelled 
NSILA by fat cells preincubated with cold NSILA (specific 
biological activity 3.8 mU/mg) without or with prior washing 
after preincubation. The experimental procedure was the 
same as in fig.2A, except that ‘*51-labelled NSILA was added 
instead of ‘251-labelled insulin. 
only 25% compared to the binding in the absence of 
cold NSILA. After washing the cells, i251-insulin was 
bound nearly to the same extent as in the absence of 
cold NSILA during preincubation. 
This was different, when ‘*‘I-NSILA was used in the 
second incubation: ‘251-NSILA binding remained 
depressed in spite of the washing procedure. These 
data are compatible with the following interpreta- 
tion: NSILA appears to have a relatively low affinity 
for the insulin binding site from which it may be 
removed by washing. There seems to be a second 
binding site which binds NSILA much more tightly 
and from which it cannot be readily removed by the 
washing procedure. Some indirect evidence that rat 
fat cells contain a NSILA-binding site different from 
that of insulin has recently been obtained by 
Solomon et al. [ 161 and by Renner and Hepp [ 171. 
Our competitive binding studies substantiate the 
findings of these authors. 
It appears reasonable to assume that NSILA exerts 
its insulin-like effects on fat cells via the insulin 
receptor (1) because the biological potency ratio 
between NSILA and insulin (- 1 : 60) lies within the 
same order of magnitude as the potency ratio for the 
displacement of 1251-insulin (- 1 : 35) and (2) because 
the ratios between the biological and the ‘251-insulin- 
displacing potency are also similar (insulin - 33 : 1, 
NSILA - 20 : 1). These findings are in contrast to 
those obtained with the rat heart where the com- 
parison between receptor binding data and the biolo- 
gical potencies of insulin and NSILA suggests that 
NSILA acts via the NSILA binding-site [ 141. It remains 
to be elucidated whether the NSILA binding site of 
adipocytes is ‘non-functional’ or if some as yet 
unknown effects are mediated through its interaction 
with NSILA. 
Acknowledgements 
This work was supported by a grant (no. 3.7180.72) 
from the Schweizerische Nationalfonds. 
References 
ill 
PI 
[31 
141 
ISI 
161 
I71 
Oelz, O., Jakob, A. and Froesch, E. R. (1970) Eur. 
J. Clin. Invest. 1, 48. 
Froesch, E. R., Mullet, W. A., Biirgi, H., Waldvogel, M. 
and Labhart, A. (1966) Biochim. Biophys. Acta 121, 
360. 
Gliemann, J. (1968) Diabetologia 4,95. 
Hcpp, D., Poffenbarger, P. L., Ensinck, J. W. and 
Williams, R. H. (1967) Metabolism 16, 393. 
Zapf, J., MIder, M., Waldvogel, M. and Froesch, E. R. 
(1975) Jsr. J. Med. Sci. 11/7,664. 
Zumstein, P., Zapf, J. and Froesch, E. R. (1974) 
FEBS Lett. 49/l, 65. 
Rodbell, M. (1964) J. Biol. Chem. 239, 375. 
178 
Volume 67, number 2 FEBS LETTERS August 1976 
[8] Humbel, R. E., Biinzli, H., Miilly, K., Oelz, 0. and 
Froesch, E. R. (1971) in:Proc. VIIth Congr. Int. Diab. 
Fed., Buenos Aires, 1970, ICS No. 231, p. 306, 
(Rodriguez, R. R. and Vallence-Owen, J., eds.) Excerpta 
Medica, Amsterdam. 
[9] Hunter, W. M. and Greenwood, F. C. (1962) Nature 
(London) 194,495. 
[IO] Zapf, J., Mader, M., Waldvogel, M., Schalch, D. S. and 
Froesch, E. R. (1975) Arch. Biochem. Biophys. 
168, 630. 
[ 111 Gammeltoft, S. and Gliemann, J. (1973) Biochim. 
Biophys. Acta 320, 16. 
[ 121 Livingston, J. N., Cuatrecasas, P. and Lockwood, D. H. 
(1972) Science 177, 626. 
[13] Megyesi, K., Kahn, C. R., Roth, J., Froesch, E. R., 
Humbel, R. E., Zapf, J. and Neville, D. M., jr. (1974) 
Biochem. Biophys. Res. Commun. 57. 307. 
[14] Meuli, C. and Froesch, E. R. (1976) Arch. Biochem. 
Biophys., in press. 
[15] Rinderknecht, E. and Humbel, R. E. (1976) Proc. Nat. 
Acad. Sci. USA, in press. 
1161 Solomon, S. S., King, L. E., jr. and Hashimoto, K. 
(1975) Horm. Metab. Res. 7, 297. 
(171 Renner, R. and flepp, K. D. (1974) Diabetologia IO, 384. 
179 
